Abstract | BACKGROUND: There is recent evidence supporting the safety and efficacy of same-day dosing of pegfilgrastim in patients undergoing chemotherapy. OBJECTIVE: MATERIALS AND METHODS: A cost-utility model was designed comparing standard D2 versus D1 administration of pegfilgrastim to ovarian cancer patients receiving chemotherapy with an intermediate risk (10-15%) of febrile neutropenia (FN). Rates of FN despite prophylaxis were modeled as 10% for D1 and 5% for D2. Societal costs associated with D2 injection ($175.71) were incorporated. Quality of life (QOL) was modeled from published data; we assumed a small decrement in QOL on treatment days. Sensitivity analyses were performed. RESULTS: D1 administration was less costly ($17,195 versus $17,681) and resulted in higher QOL (0.2298 quality adjusted life years (QALYs) versus 0.2288 QALYs) than D2. Results were sensitive to the risk of FN. D1 remained dominant or cost-effective (ICER less than $50,000/QALY) compared to D2 if the FN rate with D1 was assumed less than 14.5% (baseline estimate 10%). If the FN rate with D1 was assumed greater than or equal to 15%, D1 was not cost-effective compared to D2, with an ICER greater than $100,000/QALY. Findings are insensitive to variations in the modeled cost of treating FN, the additional cost of D2 injection, and the reduced QOL associated with treatment visits. CONCLUSION:
|
Authors | Caroline C Billingsley, David E Cohn, Aleia K Crim, Quan Li, David M O'Malley, Laura J Havrilesky |
Journal | Cancer treatment and research communications
(Cancer Treat Res Commun)
Vol. 14
Pg. 21-25
( 2018)
ISSN: 2468-2942 [Electronic] England |
PMID | 30104004
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017. Published by Elsevier Ltd. |
Chemical References |
- Antineoplastic Agents
- pegfilgrastim
- Polyethylene Glycols
- Filgrastim
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Cost-Benefit Analysis
- Drug Administration Schedule
- Febrile Neutropenia
(chemically induced, drug therapy, prevention & control)
- Female
- Filgrastim
(administration & dosage, economics)
- Humans
- Ovarian Neoplasms
(drug therapy)
- Polyethylene Glycols
(administration & dosage, economics)
- Primary Prevention
- Quality of Life
- Quality-Adjusted Life Years
- Risk Factors
|